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Circulating glucocorticoids are associated with the metabolic syndrome and related 
cardiometabolic risk factors in non-Africans. This study investigated these associations 
in Africans, whose metabolic phenotype reportedly differs from Europeans. Measures of 
adiposity, blood pressure, glycaemia, insulin resistance, and lipid profile, were 
measured in 316 African men and 788 African women living in Soweto, Johannesburg. 
The 2009 harmonized criteria were used to define the metabolic syndrome. Serum 
glucocorticoids were measured using liquid chromatography-mass spectrometry. 
Cortisol was associated with greater odds of presenting with the metabolic syndrome 
(odds ratio (95% confidence interval, 95%CI) =1.50 [1.04, 2.17] and higher systolic 
(beta coefficient, β (95%CI) =0.04 [0.01, 0.08]) and diastolic (0.05 [0.02, 0.09]) blood 
pressure, but higher HDL (0.10 [0.02, 0.19]) and lower LDL (-0.14 [-0.24, -0.03]) 
cholesterol concentrations, in the combined sample of men and women. In contrast, 
corticosterone was only associated with higher insulin sensitivity (Matsuda index; 0.22 
[0.03, 0.41]), but this was not independent of BMI. Sex-specific associations were 
observed, such that both cortisol and corticosterone were associated with higher fasting 
glucose (standardized β (95%CI): 0.24 [0.12, 0.36] for cortisol; and 0.12 [0.01, 0.23] for 
corticosterone) and HbA1c (0.13 [0.01, 0.25] for cortisol; and 0.12 [0.01, 0.24] for 
corticosterone) in men only, but lower HbA1c (0.10 [ -0.20, -0.01] for cortisol; and -0.09 
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[-0.18, -0.03] for corticosterone) in women only. Our study reports for the first time that 
associations between circulating glucocorticoid concentrations and key cardiometabolic 
risk factors exhibit both glucocorticoid- and sex-specificity in Africans.
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Elevated waist circumference, blood pressure, fasting glucose, triglycerides, and 
reduced high-density-lipoprotein (HDL) cholesterol often cluster together as 
components of the metabolic syndrome (1). Chronic exposure to excess cortisol leads 
to Cushing’s syndrome, which exhibits metabolic features similar to the metabolic 
syndrome (2). Accordingly, previous cross-sectional studies suggest that circulating 
cortisol concentrations are associated with the metabolic syndrome, its components, 
and related cardiometabolic risk factors, including measures of obesity, insulin 
resistance, and glucose intolerance (3–7). 
Cortisol may not be the only glucocorticoid involved in the metabolic syndrome, as 
humans also produce corticosterone. As cortisol production is almost ten times higher 
than corticosterone (8), previous studies have only focused on cortisol, and assumed 
that these two glucocorticoids have identical functions (9). However, recent evidence 
suggests that cortisol and corticosterone may have distinct roles in human health and 
disease (10). 
Notably, most of the reported cross-sectional studies that have explored the 
associations between cortisol and cardiometabolic risk factors were conducted in non-
Africans (3–6). Africans have a different metabolic phenotype to that of their European 
counterparts (11,12). Some studies have shown that in urban settings Africans have 
higher prevalence of obesity and insulin resistance, yet have less visceral adipose 
tissue (VAT) than Europeans (13–15). Although the mechanisms underlying these 
ethnic differences are not yet known, a recent study suggested that glucocorticoids may 
be involved (16). Goedecke et al., (16) reported that black South African women 
demonstrated lower gene expression of the glucocorticoid receptor (GR) in 
subcutaneous adipose tissue (SAT) than women of European ancestry. The lower GR 
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expression in these African women was associated with less VAT, higher SAT 
inflammation, and whole-body lower insulin sensitivity. Furthermore, some studies have 
shown that circulating cortisol concentrations are lower in African women compared to 
women of European ancestry (17,18). In support of these ethnic differences in, a study 
that included both African men and women suggested more evidence of hypothalamic-
pituitary-adrenal (HPA) axis dysregulation in African males compared to their European 
ancestry counterparts, and the HPA axis dysregulation was associated with an 
increased risk of cardiovascular disease (7). Based on the above observations, we 
hypothesized that the often-observed ethnic differences in body fat distribution, 
inflammatory profile, insulin sensitivity and circulating cortisol concentrations are partly 
explained by tissue-specific differences of glucocorticoid metabolism within SAT.
However, as studies of cortisol and the metabolic syndrome in Africans are scarce and 
none have included corticosterone, it is still uncertain whether circulating glucocorticoids 
associate with the metabolic syndrome and related cardiometabolic risk factors in 
Africans (19–21). Therefore, the aim of this study was to investigate the associations 
between fasting serum corticosterone and cortisol concentrations and the metabolic 
syndrome and related cardiometabolic risk factors in black South African men and 
women. 
MATERIALS AND METHODS 
Study population and sampling procedure
The study sample consisted of adult male and female participants recruited from various 
studies at the SAMRC/Wits Developmental Pathways for Health Research Unit, based 
at the Chris Hani Baragwanath Academic Hospital in Soweto, Johannesburg. Study 
sample 1 (ethical clearance M090620) included women recruited as part of the Africa 
Wits-INDEPTH partnership for Genomic Research (AWI-Gen) study (22). These women 
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(n=1007) who were randomly recruited between 2011 and 2013 were the caregivers of 
the Birth to Twenty Plus (Bt20+) cohort.  Bt20+ is an ongoing longitudinal study, and its 
profile has been described elsewhere (23). The majority of the caregivers of the Bt20+ 
participants are South African men and women of African ancestry who were self-
identified as South-Eastern Bantu language speakers, and only this ethnic group was 
included in the present study. Details of data collection protocols for the AWI-Gen study 
have been described elsewhere (24). Study sample 2 included participants (501 men 
and 529 women) recruited as part of a longitudinal study designed to identify the 
determinants of type 2 diabetes risk in middle-aged South African men and women 
(ethical clearance M160604). These participants were a sub-sample of the AWI-Gen 
study from whom follow-up data collected between January 2017 and August 2018 
were used and included no participants from study sample 1.
The selection of the participants for the present study was primarily based on the 
availability of serum samples for glucocorticoid determination. Participants who were 
pregnant or using corticosteroid medication were excluded from the study (Figure 1). A 
total of 1 104 participants were selected for the present study, with the selection 
process described in Figure 1. Consent was obtained from all study participants 
following full explanation of the purpose and nature of all procedures used. Further 
ethical clearance for all analyses conducted as part of the present study was also 
obtained (ethical clearance no: M160225) from the University of the Witwatersrand 
Human Research Ethics Committee (Medical). 
Participant testing procedures     
Participants were asked to remove heavy clothes and shoes prior to weight and height 
measurements. Weight was measured using a calibrated digital scale (Dismed, Halfway 
House, SA) to the nearest 0.1 kg. Standing height was measured using a fixed-wall 
stadiometer (Holtain, Crymych, UK) to the nearest 0.1 cm. Body mass index (BMI) was 
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calculated as weight (kg) divided by height squared (m2). Waist circumference was 
determined at the level of the umbilicus when the participants were standing and 
measured using a soft measuring tape to the nearest 0.5 cm. Systolic and diastolic 
blood pressure were measured on the left arm using a digital blood pressure reader 
(Omron M6, Kyoto, Japan) and appropriate cuffs. After the participant had been seated 
for at least five minutes, three blood pressure readings were taken at two-minute 
intervals, and the average of the second and third readings was recorded and used in 
the analyses. Participants who self-reported as smoking any form of tobacco and/or 
drinking any form of alcohol were classified as current smokers or drinkers, respectively.  
Participants were asked to bring their chronic medication to the interview sessions to 
confirm disease status. 
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Blood sampling and biochemical analyses 
Standard venepuncture techniques were used to collect blood samples after 10-12 
hours of fasting for the subsequent determination of serum lipids, HbA1c, serum insulin, 
plasma glucose, and serum glucocorticoid concentrations. Blood sampling time for the 
fasting samples was recorded and ranged from 07:00-11:59 am. To convert the blood 
sampling time into a more continuous variable, minutes from the earliest blood sample 
(07h00) were calculated. For example, a blood sample collected at 08h00 was assigned 
a time value of 60 minutes. A standard oral glucose tolerance test (OGTT) was 
conducted on a sub-sample of participants (Study 2 in Figure 1, n=636). During the 
OGTT, the participants ingested 75 g anhydrous glucose dissolved in 250 ml water. 
Blood samples were then collected at 30-minute intervals for 120 minutes for the 
subsequent determination of the Matsuda Index (OGTT-derived insulin sensitivity) 
(http://mmatsuda.diabetes-smc.jp/english.html) and two-hour OGTT glucose 
concentrations. 
Serum lipid concentrations, including triglycerides and total- and HDL-cholesterol, were 
measured using prescribed enzymatic methods with the RX Daytona Chemistry 
Analyzer (Randox, Crulim, UK). The inter- and intra-assay coefficients of variation (CVs) 
for the serum lipids were 1.4% and 1.5% for triglycerides, respectively, both 1.3% for 
total cholesterol, and 1.7% and 1.8% for HDL cholesterol, respectively. Serum low-
density lipoprotein (LDL)-cholesterol concentrations were calculated using the 
Friedewald equation (25). The HbA1c concentrations were measured in whole blood 
samples using the D-10 Haemoglobin testing system (BioRad, Hercules, USA), and the 
inter- and intra-assay CVs were both 1.8%. Plasma glucose concentrations were 
measured using the RX Daytona Chemistry Analyzer (Randox, Crulim, UK), and the 
Advia 1800 Chemistry Analyser (Siemens Healthcare Diagnostics, Tarrytown, USA) 
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was used to measure serum insulin concentrations. The inter- and intra-assay CVs 
were 3.3% and 1.3% for glucose, respectively, and 2.9% and 2.7% for insulin, 
respectively. The HOMA2-IR calculator version 2.2.3 was used to estimate insulin 
resistance levels (https://www.dtu.ox.ac.uk/homacalculator) from fasting serum insulin 
and plasma glucose concentrations.  
Definition of the metabolic syndrome 
The 2009 harmonized guidelines were used for the diagnosis of the metabolic 
syndrome (1). The harmonized diagnosis requires the presence of three or more of the 
following criteria: elevated waist circumference (≥94 cm in men, ≥80 cm in women), 
elevated triglyceride (≥1.7 mmol/L), low HDL cholesterol (<1.0 mmol/L in males, <1.3 
mmol/L in females), elevated blood pressure (systolic ≥130 and/or diastolic ≥85 mmHg), 
and elevated fasting glucose (≥5.6 mmol/L). The use of prescribed medications for 
elevated blood pressure and diabetes were also considered as relevant indicators of the 
presence of elevated blood pressure and fasting blood glucose concentrations, 
respectively.
Steroid extraction and glucocorticoid measurements 
Extraction of steroids from serum: All calibrators, internal standards (labelled with 
stable isotope deuterium; corticoseterone-d8 and cortisol-d4), and controls were 
purchased from Chromsystems (Grafelfing, Germany). A liquid-liquid extraction 
technique (Agilent technologies, California, United States) was used to extract all 
steroids. Briefly, 50 ul of the internal standard was added to 500 ul of serum. Three 
millilitres of methyl tert-butyl ether (MTBE) were added to each sample and vortexed at 
maximum speed for 3x30 seconds, with 30 seconds rests in between. The sample was 
then centrifuged at 3500 RPM for 10 minutes. The supernatant was transferred into a 
clean glass tube and dried down using technical grade nitrogen (Afrox, Johannesburg, 
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SA) at room temperature. The extracted steroids were reconstituted in 100 ul of 50% 
methanol:water and then transferred into limited volume analytical vials (Kinesis inc., 
Vernom Hills, USA) for analyses on the Ultra-higher Pressure Liquid Chromatography 
(UPLC) Mass Spectrometry (MS).
Glucocorticoid measurement in the UPLC-MS: Ten microliters of each extracted 
sample was injected onto a Kinetex F5 2.6 um 50x2.1 mm column (Phenomenex, 
California, USA) utilising an Acquity UPLC that was connected to a Xevo-TQS MS 
(Waters Corporation, Milford, USA). The UPLC-MS method was optimized and 
validated to quantitate both corticosterone and cortisol. A flow rate of 0.6 ml/min set on 
a gradient profile was used to elute the compounds. A binary flow mobile phase was 
used and consisted of mobile phase A: 5 mM Ammonium formate and 0.1% formic acid 
in deionized water, and mobile phase B: 1 mM Ammonium formate and 0.1% formic 
acid in acetonitrile to elute off each of the glucocorticoids over a total run time of 5.50 
minutes. The gradient programme was set as follows: 5% B for the first 0.95 min; 30% B 
for 0.5 minutes; 70% B for 0.50 minutes; this was ramped to 90% B at 1.95 minutes and 
maintained for 2.55 minutes with a final ramp to 95% B for 0.50 minutes to wash the 
column. The conditions were then changed back to initial starting conditions (5% B) at 4 
minutes to equilibrate the column. The retention time for corticosterone and 
corticosterone-d8 was 3.23 and 3.25 minutes respectively whereas the retention time 
for cortisol and cortisol-d4 was 3.35 and 3.36 minutes, respectively.
Electrospray ionisation in positive mode was used in the MS. Capillary voltage was 3 kV 
with cone and collision energies optimised to each compound analysed. Source 
temperature and desolvation temperature were set at 150 °C and 350 °C, respectively. 
Cone gas was set at 550 L/hr and desolvation gas was set at 150 L/hr. The analytes 
were identified with multiple reaction monitoring identified for each individual compound. 
Corticosterone had a transition of 347>121 as the quanitifier and 347>329 for the 
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qualifier. Cortisol utilised the transition of 363>121 for the quantifier and 363>97 for the 
qualifier. 
The inter- and intra-assay CVs for serum corticosterone were 7.3% and 2.9%, 
respectively, and for cortisol concentrations were 13.6% and 9.6%, respectively on 
control level 1 (lowest concentration).
Statistical analyses
All statistical analyses were conducted in R version 3.6.2 (26). Prior to the statistical 
analyses, the normality of the continuous variables was assessed using distribution 
graphs (QQ-plots, histograms, and box plots) as well as the Shapiro-Wilk test. None of 
the continuous variables shown in Table 1 were normally distributed and are thus 
presented as medians (25th-75th percentiles). Therefore, the Mann-Whitney U test was 
used to assess the statistical differences in the continuous variables between men and 
women (Table 1). Differences in the categorical variables (prescribed medication, 
prevalence of the metabolic syndrome, and lifestyle factors) are presented as 
observations/ total non-missing observations (n/N (%)) and were compared between 
men and women using a Chi-square test (Table 1). 
Logistic or linear regression models were used to determine associations between 
serum glucocorticoid concentrations and the metabolic syndrome and related 
cardiometabolic risk factors, respectively. Blood sampling time, age, sex, alcohol, and 
smoking were used as covariates in all regression models. Prescribed medications for 
blood pressure, diabetes and lipids were also used as covariates in regression models 
that included measures of blood pressure, measures of glycaemia and insulin 
resistance, and lipid profile. The associations between circulating glucocorticoids and 
adiposity are often confounded by the increased metabolic clearance of glucocorticoids 
within the adipose and liver tissues in obesity (27). Hence, BMI was included as an 
Page 11 of 43 Accepted Manuscript published as EC-21-0195.R1. Accepted for publication: 14-Jul-2021
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 07/20/2021 10:49:47AM
via free access
12
additional covariate in all models (except where BMI, waist circumference and the 
metabolic syndrome were the outcomes). For the regression models, all continuous 
dependent variables were log transformed to achieve normal distributions prior to 
inclusion in the models. The regression models were first conducted in the whole study 
sample comprising both men and women. In these models, sex interactions were also 
tested, and the sex interaction p values were recorded as “Sex Int”. All models showing 
evidence of sex interactions (Sex Int: p<0.05) were subsequently stratified by sex and 
each regression model was repeated in men and women separately. 
To test the validity of the linear regression models, the presence of a linear relationship 
between the serum glucocorticoid concentrations and the relevant outcome variable 
were first confirmed in each model using scatter plots. The absence of multicollinearity 
within each model was confirmed by assessing the variance inflation factor (VIF) values 
(all VIF<3.0). Finally, the validity of each linear regression model was confirmed by 
testing the normality of the residuals. 
The tested outcome variables included the metabolic syndrome, BMI, waist 
circumference, systolic and diastolic blood pressure, fasting glucose and insulin, two-
hour glucose, HOMA2-IR, Matsuda Index, and serum lipids (triglyceride, total-, LDL- 
and HDL-cholesterol). 
Data from the logistic regression models are presented as the odds ratio of presenting 
with the metabolic syndrome, for both corticosterone and cortisol, with adjustment for 
potential confounders (age, sex, blood sampling time, smoking and alcohol) (Figure 2). 
For the linear models, the beta coefficients and 95% CI for the various outcome 
measures listed above, are presented in Table 2 adjusted for the potential confounders 
only (referred as Model 1) and for the potential confounders plus BMI (referred as Model 
2). 
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The characteristics of the whole sample, and men and women separately, are 
presented in Table 1, with a comparison of the categorized components of the 
metabolic syndrome and related cardiometabolic risk factors presented in Table S1. 
Women were younger than men (p<0.001) and had a higher BMI (p<0.001) and waist 
circumference (p=0.029) (Table 1). Accordingly, a greater proportion of women were 
classified with obesity (65.2% vs 25.3%; p<0.001) and with a waist circumference 
greater than that of the metabolic syndrome cut points (88.3% vs 48.4%; p<0.001) 
(Table S1). 
Despite differences in obesity, fasting glucose was similar between men and women. 
However, compared to men, women had higher fasting insulin, HOMA2-IR, two-hour 
glucose, HbA1c concentrations, and lower insulin sensitivity (Matsuda index) (all 
p<0.001). Although a larger proportion of women were using diabetes medication 
(11.2% vs 6.1%; p=0.022) than men (Table 1), when using the metabolic syndrome 
criteria (fasting blood glucose ≥5.6 mmol/l and/or using diabetes medication) the 
proportion of men and women with elevated blood glucose did not differ (Table S1).
Although HDL-cholesterol and triglycerides did not differ by sex, total cholesterol and 
LDL-cholesterol concentrations were higher in women compared to men (p<0.001 for 
both) (Table 1). Moreover, a greater proportion of women had low HDL cholesterol 
(57.0% vs 18.0%), but the prevalence of elevated triglycerides was greater in men (15.2 
vs 8.2%) (p<0.001 for both) (Table S1). There were no observed differences in the use 
of cholesterol-lowering medication between the sexes. 
Systolic and diastolic blood pressure were both higher in men (p=0.017 and p=0.003, 
respectively) (Table 1), and this finding was accompanied by a greater proportion of 
Page 13 of 43 Accepted Manuscript published as EC-21-0195.R1. Accepted for publication: 14-Jul-2021
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 07/20/2021 10:49:47AM
via free access
14
men having elevated systolic (≥130 mmHg and/or using blood pressure medication, 
53.0% vs 46.3%; p=0.017), diastolic (≥85 mmHg and/or using blood pressure 
medication, 61.3 vs 52.8%; p=0.003), and overall blood pressure (73.4% vs 66.5%; 
p=0.030) (Table S1). In contrast, a greater proportion of women used blood pressure 
medication (37.9% vs 27.1%; p=0.002). 
A greater proportion of women than men were classified as having the metabolic 
syndrome (47.6% vs 26.3%; p<0.001). Meanwhile, a greater proportion of men smoked 
(50.8% vs 8.3%; p<0.001) and drank alcohol (71.7% vs 28.7%; p<0.001) compared to 
women.
When comparing the serum glucocorticoid concentrations (Table 1), women had higher 
serum concentrations of both corticosterone (p<0.001) and cortisol (p<0.002). These 
differences were accompanied by later average blood sampling times (measured as 
minutes from the earliest blood sampling time) in women compared to men (p<0.001). 
Notably, the sex differences in serum glucocorticoid concentrations were observed even 
after adjusting for sampling time, measures of adiposity (BMI and waist circumference), 
and/or other potential confounders (age, smoking, alcohol) (results not shown).
Associations with the metabolic syndrome and related 
cardiometabolic risk factors in black South Africans 
Only regression models that either showed evidence of associations (p<0.05) or sex-
interaction (Sex Int: p<0.05) are presented in Figure 2 and Table 2. The unadjusted 
models and all other models that were tested are presented in Table S2. Figure 2 
shows that serum cortisol but not corticosterone concentrations were associated with 
greater odds of presenting with the metabolic syndrome. The association between 
circulating glucocorticoids and the metabolic syndrome did not differ by sex (Sex Int: 
p=0.142 for corticosterone and p=0.245 for cortisol). 
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There was no evidence of association between corticosterone and cortisol and 
measures of adiposity (BMI and waist circumference) (Table 2). However, there was a 
sex-interaction for the association between serum cortisol concentration and BMI (Table 
2), but the sex-stratified analyses revealed no sufficient evidence of association (Figure 
3). There was no evidence of sex interaction in the associations between either of the 
serum glucocorticoid measures and waist circumference.
Serum cortisol, but not corticosterone, concentrations were associated with higher 
systolic (p=0.028) and diastolic (p=0.004) blood pressure, even after adjusting for BMI 
(p=0.018 and p=0.002, respectively). These associations did not differ by sex (Table 2). 
No evidence of association for serum corticosterone and cortisol concentrations were 
observed with measures of glycaemia in the combined sample of men and women. 
However, there was evidence of sex-interactions for associations with fasting blood 
glucose (Sex Int: p=0.009 and p<0.001, respectively) and HbA1c (Sex Int: p=0.003 for 
both) concentrations (Table 2, Figure 3). These sex-interactions were present even after 
adjusting for BMI. Subsequent sex-stratified analyses revealed that both serum 
corticosterone and cortisol concentrations were associated with higher fasting blood 
glucose (p=0.040 and p<0.001, respectively) and HbA1c (p=0.035 and p=0.030, 
respectively) concentrations in men only, but lower HbA1c concentrations (p=0.042 and 
p=0.030, respectively) in women only (Figure 3). Although the association between 
serum cortisol and two-hour OGTT glucose concentrations showed a sex-interaction 
after adjusting for BMI (Sex Int: p=0.047), sex-stratified analyses revealed no evidence 
of association in either sex (Table 2, Figure 3).
Serum corticosterone, but not cortisol, was associated with higher insulin sensitivity 
(Matsuda index, p=0.021), but the association was no longer present after adjusting for 
BMI (p=0.122) (Table 2). Neither of the glucocorticoids were associated with fasting 
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insulin concentrations or HOMA-IR. Moreover, there was no evidence of sex 
interactions for any measure of insulin resistance. 
Serum cortisol concentrations were associated with lower LDL (p=0.009) and higher 
HDL (p=0.020) cholesterol (Table 2). These associations remained even after adjusting 
for BMI (p=0.009 and 0.017, respectively). While serum corticosterone concentrations 
were not associated with any of the serum lipid concentrations, there was evidence of 
sex-interaction for LDL cholesterol (Sex Int: p=0.019) which was not altered by inclusion 
of BMI (Sex Int: p=0.029) (Table 2). However, sex-stratified analyses revealed no 
evidence of sex-specific associations for LDL cholesterol concentrations (Figure 3). In 
contrast, although there was evidence of a sex interaction for HDL cholesterol 
concentrations (Sex Int: p=0.038), this was not observed after including BMI as a 
covariate. 
DISCUSSION 
We have shown for the first time that associations between circulating glucocorticoid 
concentrations and key cardiometabolic variables are both glucocorticoid- and sex-
specific in black South Africans. 
The higher prevalence of the metabolic syndrome in women compared to men in the 
present study (45.8% vs 27.8%) was in accordance with previous studies in African 
populations (28). However, this is the first study to show that fasting serum cortisol 
concentrations were associated with greater odds of having the metabolic syndrome in 
a combined sample of African men and women. This observation is in accordance with 
cross-sectional studies from Asian and European populations, which demonstrated that 
individuals with the metabolic syndrome had higher circulating cortisol concentrations 
compared to those without the metabolic syndrome (6,29). The relationship between 
circulating cortisol concentrations and the metabolic syndrome may have been 
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attributed to underlying associations of cortisol with the individual components of the 
metabolic syndrome. In this study, the relationship between cortisol and the metabolic 
syndrome was largely driven by blood pressure as there was no evidence of association 
with waist circumference or triglycerides, while the association was positive with HDL 
cholesterol and showed sex-specificity for fasting glucose.    
The finding that cortisol, but not corticosterone, concentrations were associated with 
higher systolic and diastolic blood pressure was in accordance with previous studies 
demonstrating that circulating cortisol concentrations were associated with both systolic 
and diastolic blood pressure in Africans, Asians and Europeans (19–21,30,31). A study 
that has investigated circulating corticosterone in Europeans demonstrated that the 
associations between corticosterone concentrations and systolic blood pressure were 
weaker than those demonstrated for cortisol, and corticosterone was not associated 
with systolic blood pressure in other independent European cohorts (Mackenzie SD, 
Crawford AA, Ackermann D, Schraut KE, Hayward C, Bolton JL, Saunders C, Al-Dujaili 
E, Dick B, Escher G, Vogt B, Pruijm M, Ponte B, Wilson JF, Strachan MWJ, Price JF, 
Phillips DIW, MacKenzie SM, Davies E, Reynolds RM & Walker BR, unpublished 
observations). Glucocorticoids influence blood pressure via several mechanisms which 
are thought to occur through binding of the GR or mineralocorticoid receptor (MR) in the 
kidneys or vascular system (32). For example, in the kidneys, glucocorticoids impair 
nitric oxide-mediated renal vasodilation (33) possibly by suppressing nitric oxide 
synthase, but also influence salt and water retention, ultimately increasing blood 
pressure (34). There is, however, no strong evidence to suggest that corticosterone and 
cortisol bind differently to the GR or MR and that these mechanisms are directly 
involved in the different associations of the two glucocorticoids with blood pressure 
(35,36). It is unlikely that the glucocorticoid-specific associations with blood pressure 
were due to lower circulating corticosterone concentrations compared to cortisol (6.3 
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versus 182.5 nmol/L), as there was evidence of an association between corticosterone 
and measures of insulin sensitivity, in the present study. While future studies are still 
required to confirm that corticosterone induces the GR or MR response at these low 
concentrations in humans, animal studies have suggested that these glucocorticoid-
specific associations may be related to differential transmembrane transport by ABC 
transporters (10,37,38). This hypothesis originates from the fact that cortisol and 
corticosterone differ in their susceptibility to transmembrane transport by ABC 
transporters. For example, ABCB1 is an ABC transporter that is highly expressed in the 
central nervous system (CNS), and selectively exports cortisol but not corticosterone 
across the blood-brain barrier (38). Consequently, while corticosterone concentrations 
are approximately 5% the concentration of cortisol in the blood, the concentrations are 
much higher (~30%) in the cerebrospinal fluid (39). Thus, corticosterone may contribute 
disproportionately to the negative feedback control of the HPA axis within the CNS. As 
both glucocorticoids similarly bind to the GR and MR to increase blood pressure (33), 
higher circulating concentrations of corticosterone are accompanied by a more robust 
HPA axis regulatory response, in comparison to cortisol, to inhibit overall excess 
glucocorticoid production, ultimately lowering insulin resistance and blood pressure (38).     
Additionally, it has been suggested that the relationship between glucocorticoids and 
elevated blood pressure may be partly mediated by adiposity (40), which is often 
associated with the other related cardiometabolic risk factors (1). However, adjusting for 
either BMI or waist circumference did not alter the relationship with blood pressure in 
our study. Further, there was no evidence of associations between the glucocorticoids 
and measures of adiposity in this study. It is possible that the overall effects on BMI and 
waist circumference were confounded by sex differences in body fat distribution and 
consequent differences in glucocorticoid clearance, as men generally accumulate more 
VAT compared to women, and glucocorticoid clearance is higher in VAT compared to 
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SAT (41). In this study, men had lower prevalence of obesity and elevated waist 
circumference compared to women (25.3 versus 65.2% and 48.4 versus 88.3%, 
respectively), and there was evidence of sex interaction in the association between 
cortisol and BMI (p value for sex interaction =0.040). Although sex-stratified analyses 
revealed that the association between cortisol and BMI was negative in men but positive 
in women, there was not sufficient evidence (p>0.05) for these relationships in our study 
sample. Hence, further studies that include larger samples of men and women are 
required to explore these sex-specific interactions. 
Although there was no association between cortisol and insulin resistance, we have 
shown for the first time that corticosterone was associated with higher insulin sensitivity, 
as assessed using the Matsuda index. However, this relationship was not present after 
adjusting for BMI. This finding highlights the importance of including BMI as an 
additional covariate in glucocorticoid studies, and supports the notion that circulating 
glucocorticoids are associated with adiposity but the relationship is confounded by other 
factors such as increased metabolic clearance in obesity and type 2 diabetes (27).  
This study has also demonstrated that cortisol was associated with a favourable lipid 
profile (lower serum LDL and higher HDL cholesterol) in black South Africans. Studies 
from non-Africans that investigated the relationship between circulating cortisol and 
serum lipid concentrations are inconsistent (29–31,42,43). Although some studies 
reported no association between circulating cortisol and HDL cholesterol (29,30), other 
studies reported an inverse association (31), whilst another reported a positive 
association (42). Likewise, while some studies have demonstrated a positive 
association between circulating cortisol and LDL cholesterol (43), other studies showed 
no evidence of this association (29,30). These contradictory findings were thought to be 
related to differences in age and BMI between the various studies. However, in the 
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present study, the associations between serum cortisol and HDL and LDL cholesterol 
were independent of BMI, negating the involvement of adiposity-related mechanisms. 
Indeed, further studies are necessary to understand the exact mechanisms involved.
In addition to glucocorticoid-specific associations, findings from the present study 
suggested for the first-time that both serum corticosterone and cortisol showed sex-
specific associations with measures of glycaemia. Both fasting serum cortisol and 
corticosterone concentrations were associated with higher fasting plasma glucose and 
HbA1c concentrations in men only, but lower HbA1c concentrations in women only. As 
these sex-specific associations were similar for both corticosterone and cortisol, 
mechanisms may involve sex differences in glucocorticoid signaling in the liver, as 
demonstrated in rodent models. Mice treated with dexamethasone (a synthetic 
glucocorticoid) demonstrated several sex-specific transcriptional responses in the 
hepatic tissue (44,45). Moreover, another study showed that chronic exposure to 
excess glucocorticoid concentrations increased circulating glucose concentrations in 
male mice, but female mice were protected from these effects (46). Both corticosterone 
and cortisol are known to increase circulating glucose concentrations by promoting 
gluconeogenesis in the liver (47). Hence, sex disparities in glucocorticoid signaling 
within the liver may partly explain the observed sex-specific associations between 
circulating glucocorticoids and measures of glycaemia, which in turn may be mediated 
by sex hormones and body fat distribution (48). Indeed, disparities in sex hormone and 
body fat distribution profiles are profound between men and women. In men, 
testosterone predominates, and fat is preferentially stored as VAT, whilst in women, 
estrogen predominates and fat is preferentially stored as SAT (45). Such differences 
may have explained the observed sex-specific associations in the present study. Both 
sex hormones and fat distribution have been shown to potentially modulate responses 
to glucocorticoids (48). For example, estrogen increases corticosteroid binding globulin, 
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the primary glucocorticoid-binding protein in circulation, consequently increasing 
biologically active glucocorticoids (49). Likewise, the GR is more highly expressed in 
VAT than SAT (50). Therefore, further studies are required to investigate the role of 
hepatic glucocorticoid signaling and interactions with sex hormones and body fat 
distribution, in the observed sex-specific associations.  
This study has some limitations. The role of body distribution, menopausal status, and 
oral contraceptive use were not assessed in the present study. These factors are known 
to influence circulating glucocorticoid concentrations and may have influenced some of 
the reported results (41,51). Women were overrepresented in the present study, and 
this is common in many epidemiological studies in Africans (52). Although associations 
with several outcome variables were tested, adjustment for multiple testing was not 
conducted. However, as the outcomes are all thought to be interrelated cardiometabolic 
risk factors, adjusting for multiple testing may be too conservative and limit the 
probability of showing true effects. Additionally, circulating glucocorticoids are often 
measured at a set time (e.g., 8:00 or 9:00 am) due to their diurnal nature. Notably, blood 
sample times in the present study varied widely. However, all samples were taken in the 
morning and blood sampling time was adjusted for in all models. 
Regardless of these limitations, this is the largest study to date that has compared the 
associations of both corticosterone and cortisol concentrations with the metabolic 
syndrome and its components and related cardiometabolic risk factors in African men 
and women. This study used a UPLC-MS method for measuring glucocorticoid 
concentrations which is preferred due to its high specificity and sensitivity. In addition, 
all known confounders including sampling time, age, sex, relevant medication, smoking, 
alcohol, and adiposity, were adjusted for in the statistical analyses.  
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In conclusion, this study shows that circulating glucocorticoid concentrations are 
associated with the metabolic syndrome and related cardiometabolic variables in 
African men and women, but that these associations were glucocorticoid- and sex-
specific. Future studies should investigate the mechanisms involved, and ensure that 
both cortisol and corticosterone, and sex interactions are explored.
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Figure 1 Selection of the study sample.
Figure 2 Associations between glucocorticoids and the metabolic syndrome. 
95% CI: 95% confidence intervals; p: p value for the logistic regression model; Sex Int: p value for sex 
interaction Models adjusted for age, blood sampling time, sex, smoking, and alcohol.
Figure 3 Sex-stratified associations of corticosterone and cortisol with cardiometabolic 
risk factors.
95% CI: 95% confidence intervals. Models adjusted for age, blood sampling time, smoking, alcohol, 
relevant medication, and BMI * p value <005; # p value <0001.
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Table 1 Characteristics of the study participants.
n All (n =1104) Men (n =316) Women (n =788) p
Age and adiposity
Age (years) 1096 51.9 (46.8-57.0) 53.0 (48.1-59.0) 51.0 (46.0-56.3) <0.001
BMI (kg/m2) 1094 30.7 (25.2-35.8) 25.2 (21.0-30.1) 32.8 (28.1-37.3) <0.001
Waist circumference (cm) 1066 95.0 (86.0-104.5) 93.0 (81.8-103.8) 96.0 (87.2-105.0) 0.029
Blood pressure
Systolic blood pressure 
(mmHg)
1076 128.2 (115.5-142.8) 131.0 (118.2-145.0) 127.0 (114.0-142.5) 0.017
Diastolic blood pressure 
(mmHg)
1076 86.0 (78.0-94.7) 87.5 (80.5-96.0) 85.5 (76.5-94.0) 0.003
Glycaemia and insulin 
resistance
Fasting glucose (mmol/L) 1038 5.0 (4.5-5.5) 5.0 (4.4-5.4) 5.0 (4.5-5.6) 0.147
Fasting insulin (µIU/ml) 964 8.0 (4.4-13.9) 5.8 (2.3-11.7) 9.1 (5.2-14.6) <0.001
Two-hour glucose 
(mmol/L)
636 5.9 (4.7-7.1) 5.7 (4.3-6.7) 6.0 (5.0-7.3) <0.001
HbA1c (%) 873 5.8 (5.4-6.2) 5.5 (5.2-6.1) 5.8 (5.5-6.3) <0.001








1012 4.3 (3.7-5.0) 4.1 (3.5-4.8) 4.4 (3.8-5.1) <0.001
LDL cholesterol (mmol/L) 1012 2.7 (2.1-3.3) 2.4 (1.8-3.0) 2.8 (2.2-3.4) <0.001
HDL cholesterol (mmol/L) 1013 1.2 (1.0-1.4) 1.2 (1.0-1.5) 1.2 (1.0-1.4) 0.148
Triglycerides (mmol/L) 1012 0.9 (0.7-1.2) 0.9 (0.7-1.3) 0.9 (0.7-1.2) 0.253
Glucocorticoids 
Blood sampling time 
(min)
1027 90.0 (60.0-140.0) 54.0 (40.0-74.8) 113.0 (75.0-165.0) <0.001
Corticosterone (nmol/L) 924 6.3 (3.5-13.6) 5.0 (3.3-9.0) 6.8 (3.6-17.9) <0.001
Cortisol (nmol/L) 972 182.5 (79.5-342.5) 153.8 (76.3-295.8) 201.2 (82.5-371.9) 0.002
Medication 
Blood pressure med (n/N 
(%))
854 290/ 854 (34.0) 84/ 310 (27.1) 206/ 544 (37.9) 0.002
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Diabetes med (n/N (%)) 792 73/ 792 (9.2) 19/ 310 (6.1) 54/ 482 (11.2) 0.022
Cholesterol-lowering med 
(n/N (%))
895 61/ 895 (6.8) 21/ 310 (6.8) 40/ 585 (6.8) 1.000
Metabolic syndrome
Prevalence (2009 
harmonized definition) (n/N 
(%))
1066 440/ 1066 (40.7) 83/ 316 (26.3) 357/ 750 (47.6) <0.001
Lifestyle 
Smoking (n/N (%)) 1084 224/ 1084 (20.7) 160/ 315 (50.8) 64/ 769 (8.3) <0.001
Alcohol (n/N (%)) 674 329/ 674 (48.8) 226/ 315 (71.7) 103/ 359 (28.7) <0.001
Continuous data presented as median (25th-75th percentiles) and categorical data presented as n (%) A Wilcoxon Rank Sum 
test was used to statistically compare the continuous variables, whilst a chi-square test was used to statistically compare the 
categorical variables n: Number of observations; N: Total number of non-missing observations; min: Minutes from the earliest 
sampling time (07h00); Med: Medication; p: P value of the Wilcoxon Rank Sum statistical or Chi-square test.
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Table 1 Associations of glucocorticoids with cardiometabolic risk factors in African 
men and women.
    Model 1 (Adjusted for confounders) Model 2 (Adjusted for confounders and BMI)
Beta (95% CI) p Sex Int Beta (95% CI) p Sex Int
Corticosterone -0.046 (-0.096, 0.004) 0.071 0.063
BMI
Cortisol -0.011 (-0.064, 0.041) 0.679 0.040
Corticosterone 0.007 (-0.029, 0.043) 0.714 0.656 0.014 (-0.021, 0.049) 0.430 0.956
Systolic BP
Cortisol 0.042 (0.005, 0.079) 0.028 0.955 0.043 (0.007, 0.080) 0.018 0.634
Corticosterone 0.009 (-0.023, 0.041) 0.572 0.897 0.016 (-0.016, 0.047) 0.324 0.775
Diastolic BP
Cortisol 0.051 (0.017, 0.085) 0.004 0.918 0.052 (0.019, 0.085) 0.002 0.546
Corticosterone -0.008 (-0.055, 0.039) 0.739 0.009 -0.001 (-0.048, 0.046) 0.953 0.008
Fasting Glucose
Cortisol 0.042 (-0.010, 0.094) 0.110 <0.001 0.044 (-0.008, 0.095) 0.097 <0.001
Corticosterone -0.017 (-0.099, 0.065) 0.683 0.971 -0.001 (-0.082, 0.079) 0.972 0.824
Two-hour Glucose
Cortisol -0.013 (-0.099, 0.074) 0.775 0.090 -0.010 (-0.095, 0.075) 0.810 0.047
Corticosterone -0.013 (-0.045, 0.019) 0.435 0.003 -0.010 (-0.042, 0.022) 0.543 0.002
HbA1c
Cortisol -0.001 (-0.036, 0.035) 0.965 0.003 -0.001 (-0.036, 0.035) 0.974 0.001
Corticosterone 0.220 (0.034, 0.407) 0.021 0.444 0.134 (-0.036, 0.303) 0.122 0.921
Matsuda Index
Cortisol 0.083 (-0.117, 0.284) 0.415 0.572 0.048 (-0.133, 0.229) 0.603 0.848
Corticosterone -0.095 (-0.193, 0.003) 0.057 0.019 -0.086 (-0.184, 0.012) 0.085 0.029
LDL Cholesterol
Cortisol -0.138 (-0.241, -0.034) 0.009 0.565 -0.136 (-0.239, -0.034) 0.009 0.768
Corticosterone 0.018 (-0.066, 0.102) 0.678 0.263 -0.009 (-0.088, 0.071) 0.830 0.377
HDL Cholesterol
Cortisol 0.105 (0.017, 0.193) 0.020 0.038 0.102 (0.019, 0.186) 0.017 0.083
Beta: Beta coefficient; 95% CI: 95% confidence intervals; p: p value for the linear regression model; Sex Int: p value for sex interaction Confounders: Age, 
blood sampling time, sex, smoking, alcohol, and relevant medication  
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Figure 1 Selection of the study sample. 
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Figure 2 Associations between glucocorticoids and the metabolic syndrome. 
95% CI: 95% confidence intervals; p: p value for the logistic regression model; Sex Int: p value for sex 
interaction Models adjusted for age, blood sampling time, sex, smoking, and alcohol. 
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Figure 3 Sex-stratified associations of corticosterone and cortisol with cardiometabolic risk factors. 
95% CI: 95% confidence intervals. Models adjusted for age, blood sampling time, smoking, alcohol, relevant 
medication, and BMI * p value <005; # p value <0001. 
127x81mm (120 x 120 DPI) 
Page 38 of 43Accepted Manuscript published as EC-21-0195.R1. Accepted for publication: 14-Jul-2021
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 07/20/2021 10:49:47AM
via free access
 
Figure 3 Sex-stratified associations of corticosterone and cortisol with cardiometabolic risk factors. 
95% CI: 95% confidence intervals. Models adjusted for age, blood sampling time, smoking, alcohol, relevant 
medication, and BMI * p value <005; # p value <0001. 
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Supplementary Table 1 Summary of the categorical variables of the study sample.  
n All (n =1104) Men (n =316) Women (n =788) p
Adiposity
BMI categories 1094 <0.001
Underweight (< 18.5 kg/m2) 42 (3.8) 31 (9.8) 11 (1.4)
Normal (18.5 – 24.9 kg/m2) 222 (20.3) 125 (39.5) 97 (12.5)
Overweight (25–29.9 kg/m2) 243 (22.2) 80 (25.3) 163 (21.0)
Obese (≥30 kg/m2) 587 (53.7) 80 (25.3) 507 (65.2)
Elevated waist circumference (≥80 cm in 
women; ≥94 cm in men)
1066 849 (79.6) 153 (48.4) 696 (88.3) <0.001
Blood pressure (BP)
Elevated systolic BP (≥130 mmHg) 1076 519 (48.2) 167 (53.0) 352 (46.3) 0.017
Elevated diastolic BP (≥85 mmHg) 1076 595 (55.3) 193 (61.3) 402 (52.8) 0.003
Elevated BP (Elevated systolic and/or 
diastolic BP and/or using of BP medication)
1104 756 (68.5) 232 (73.4) 524 (66.5) 0.030
Glycaemia 
Fasting glucose (FG) categories 1038 0.023
Normal FG (<5.6 mmol/L) 791 (76.4) 251 (79.4) 540 (74.7)
Impaired FG (5.6-6.9 mmol/L) 161 (15.5) 50 (15.8) 111 (15.4)
Elevated FG (≥7.0 mmol/L) 86 (8.2) 15 (4.7) 71 (9.8)
Elevated blood glucose 
(Elevated FG and/or using diabetes 
medication)




1012 105 (10.4) 48 (15.2) 57 (8.2) <0.001
Reduced fasting HDL-cholesterol
(<1.0 mmol/L in men, <1.3 mmol/L in women)
1013 455 (44.9) 57 (18.0) 398 (57.0) <0.001
Data presented as n (%). All categorical variables were statistically compared between sexes using a chi-square test. N: Number of observations; 
BMI: Body Mass Index; blood pressure; BP: Blood pressure; FG: Fasting glucose; HDL: High Density Lipoprotein; P: P value of the chi-square 
test conducted.
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Supplementary Table 2 All regression models tested in the combined sample of African men and women.  
Unadjusted Model Model 1 (Adjusted for confounders) Model 2 (Adjusted for confounders and BMI)
Dependent variable Beta/OR 95% CI p Sex Int Beta/OR 95% CI p Sex Int Beta/OR 95% CI p Sex Int
BMI 0.005 (-0.033, 0.043) 0.794 0.173 -0.046 (-0.096, 0.004) 0.071 0.063 N/A N/A N/A N/A
Waist circumference -0.011 (-0.034, 0.013) 0.375 0.274 -0.030 (-0.065, 0.005) 0.089 0.123 N/A N/A N/A N/A
Systolic BP 0.010 (-0.015, 0.035) 0.437 0.633 0.007 (-0.029, 0.043) 0.714 0.656 0.014 (-0.021, 0.049) 0.430 0.956
Diastolic BP -0.003 (-0.025, 0.020) 0.809 0.786 0.009 (-0.023, 0.041) 0.572 0.897 0.016 (-0.016, 0.047) 0.324 0.775
Fasting glucose* -0.032 (-0.071, 0.007) 0.113 0.031 -0.008 (-0.055, 0.039) 0.739 0.009 -0.001 (-0.048, 0.046) 0.953 0.008
Fasting insulin 0.092 (-0.040, 0.223) 0.172 0.064 -0.119 (-0.301, 0.063) 0.200 0.219 -0.031 (-0.191, 0.129) 0.705 0.446
Two-hour glucose -0.008 (-0.093, 0.077) 0.854 0.791 -0.017 (-0.099, 0.065) 0.683 0.971 -0.001 (-0.082, 0.079) 0.972 0.824
HbA1c* -0.016 (-0.047, 0.014) 0.301 0.007 -0.013 (-0.045, 0.019) 0.435 0.003 -0.010 (-0.042, 0.022) 0.543 0.002
HOMA2-IR 0.077 (-0.057, 0.211) 0.261 0.083 -0.129 (-0.312, 0.055) 0.170 0.300 -0.045 (-0.205, 0.116) 0.586 0.551
Matsuda index 0.228 (0.042, 0.415) 0.017 0.560 0.220 (0.034, 0.407) 0.021 0.444 0.134 (-0.036, 0.303) 0.122 0.921
Total cholesterol -0.009 (-0.047, 0.029) 0.653 0.077 -0.053 (-0.108, 0.001) 0.056 0.060 -0.053 (-0.108, 0.002) 0.060 0.077
LDL cholesterol* -0.007 (-0.075, 0.062) 0.850 0.012 -0.095 (-0.193, 0.003) 0.057 0.019 -0.086 (-0.184, 0.012) 0.085 0.029
HDL cholesterol -0.024 (-0.084, 0.036) 0.431 0.042 0.018 (-0.066, 0.102) 0.678 0.263 -0.009 (-0.088, 0.071) 0.830 0.377








Metabolic syndrome 0.983 (0.730, 1.321) 0.908 0.392 1.104 (0.792, 1.540) 0.558 0.142 NA NA NA NA
BMI* 0.017 (-0.024, 0.059) 0.414 0.086 -0.011 (-0.064, 0.041) 0.679 0.040 N/A N/A N/A N/A
Waist circumference 0.008 (-0.018, 0.034) 0.540 0.085 0.000 (-0.016, 0.016) 0.984 0.055 N/A N/A N/A N/A
Systolic BP 0.036 (0.009, 0.063) 0.009 0.942 0.042 (0.005, 0.079) 0.028 0.955 0.043 (0.007, 0.080) 0.018 0.634
Diastolic BP 0.046 (0.022, 0.070) 1.790 x10-4 0.954 0.051 (0.017, 0.085) 0.004 0.918 0.052 (0.019, 0.085) 0.002 0.546
Fasting glucose* 0.027 (-0.017, 0.072) 0.229 0.010 0.042 (-0.010, 0.094) 0.110 <0.001 0.044 (-0.008, 0.095) 0.097 <0.001
Fasting insulin 0.040 (-0.106, 0.186) 0.589 0.027 -0.065 (-0.261, 0.131) 0.516 0.073 -0.055 (-0.226, 0.117) 0.534 0.352





HbA1c* -0.009 (-0.044, 0.026) 0.619 0.022 -0.001 (-0.036, 0.035) 0.965 0.003 -0.001 (-0.036, 0.035) 0.974 0.001
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HOMA2-IR 0.025 (-0.124, 0.175) 0.739 0.072 -0.057 (-0.254, 0.141) 0.573 0.241 -0.036 (-0.208, 0.137) 0.685 0.658
Matsuda index -0.054 (-0.248, 0.141) 0.589 0.128 0.083 (-0.117, 0.284) 0.415 0.572 0.048 (-0.133, 0.229) 0.603 0.848
Total cholesterol 0.007 (-0.037, 0.050) 0.764 0.955 -0.048 (-0.106, 0.010) 0.102 0.690 -0.048 (-0.106, 0.010) 0.104 0.573
LDL cholesterol -0.007 (-0.082, 0.067) 0.846 0.038 -0.138 (-0.241, -0.034) 0.009 0.565 -0.136 (-0.239, -0.034) 0.009 0.768
HDL cholesterol 0.037 (-0.027, 0.102) 0.254 0.014 0.105 (0.017, 0.193) 0.020 0.038 0.102 (0.019, 0.186) 0.017 0.083
Triglycerides 0.073 (0.071, -0.006) 0.152 0.651 -0.032 (-0.146, 0.081) 0.577 0.708 -0.030 (-0.141, 0.081) 0.598 0.394
Metabolic syndrome 1.397 (1.005, 1.946) 0.047 0.251 1.502 (1.044, 2.170) 0.029 0.245 NA NA NA NA
Unadjusted Model: Unadjusted linear/logistic regression model; Model 1 (Adjusted for confounders): Linear/logistic regression model adjusted for age, sex, time of blood sample (calculated 
as minutes from the earliest sample (07h00)), smoking, alcohol, and relevant chronic medication; Model 2 (Adjusted for confounders and BMI): Linear/logistic regression model adjusted 
the above confounders and BMI. Beta/OR: regression co-efficient/odds ratio value of the linear/logistic model; 95% CI: 95% confidence intervals; p: P value of the regression model; Sex Int: 
P value for the sex interaction.
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